PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 70M 140M 210M FY09: 135K FY10: 1.7M FY11: 33.9M FY12: 26M FY13: 28.2M FY14: 60.6M FY15: 92.8M FY16: 90.7M FY17: 93.5M FY18: 78.6M FY19: 90.9M FY20: 78.9M FY21: 130.5M FY22: 128.3M FY23: 200.5M FY24: 154M FY25: 160M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 25M 50M 75M FY09: 135K FY10: 1.7M FY11: 13M FY12: 940K FY13: 6.4M FY14: 23.4M FY15: 53.5M FY16: 44.2M FY17: 34.7M FY18: 25.1M FY19: 34.6M FY20: 32.6M FY21: 58.9M FY22: 49M FY23: 52.8M FY24: 37.3M FY25: 45.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-600M -400M -200M 0 200M 400M 600M FY11: -109.8M FY12: -94.3M FY13: -77.5M FY14: -62.9M FY15: -29.1M FY16: -71.2M FY17: -89.8M FY18: -101M FY19: -100.5M FY20: -104.4M FY21: -210.4M FY22: -307.2M FY23: -334.5M FY24: -474.3M FY25: -553.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-600M -400M -200M 0 200M 400M 600M FY09: -87.7M FY10: -140.2M FY11: -109.4M FY12: -94.5M FY13: -79.3M FY14: -66.2M FY15: -31.7M FY16: -74.4M FY17: -92.2M FY18: -102.6M FY19: -84.1M FY20: 29.4M FY21: -181.2M FY22: -314.2M FY23: -306.7M FY24: -309.9M FY25: -546.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 60M 120M 180M FY11: 20.8M FY12: 25M FY13: 21.8M FY14: 37.2M FY15: 39.3M FY16: 46.6M FY17: 58.8M FY18: 53.5M FY19: 56.3M FY20: 46.3M FY21: 71.7M FY22: 79.3M FY23: 147.7M FY24: 116.7M FY25: 114.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-270M -180M -90M 0 90M 180M 270M FY09: -74.8M FY10: -122M FY11: -103M FY12: -76.8M FY13: -29.8M FY14: -51.5M FY15: -47.9M FY16: -67.9M FY17: -67.5M FY18: -66.4M FY19: -78.3M FY20: 19.5M FY21: -111.2M FY22: -263.2M FY23: -259.2M FY24: -206.1M FY25: -111.2M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M FY09: -80M FY10: -127.3M FY11: -112.3M FY12: -78.5M FY13: -30.7M FY14: -53.1M FY15: -50.9M FY16: -76.1M FY17: -78M FY18: -68.3M FY19: -81.1M FY20: 18.5M FY21: -117.1M FY22: -280M FY23: -268M FY24: -212.2M FY25: -113.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 150M 300M 450M FY18: 135.1M FY19: 152.5M FY20: 175M FY21: 204.1M FY22: 224.6M FY23: 253.6M FY24: 288.4M FY25: 300M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q4 '11: -2.03 Q1 '12: -1.87 Q2 '12: -1.85 Q3 '12: -1.72 Q4 '12: -1.69 Q1 '13: -1.56 Q2 '13: -1.49 Q3 '13: -1.39 Q4 '13: -1.26 Q1 '14: -1.17 Q2 '14: -1.11 Q3 '14: -0.93 Q4 '14: -0.94 Q1 '15: -0.93 Q2 '15: -0.82 Q3 '15: -0.67 Q4 '15: -0.42 Q1 '16: -0.38 Q2 '16: -0.43 Q3 '16: -0.64 Q4 '16: -0.83 Q1 '17: -0.86 Q2 '17: -0.91 Q3 '17: -0.91 Q4 '17: -0.88 Q1 '18: -0.82 Q2 '18: -0.73 Q3 '18: -0.73 Q4 '18: -0.77 Q1 '19: -0.77 Q2 '19: -0.76 Q3 '19: -0.76 Q4 '19: -0.55 Q1 '20: -0.34 Q2 '20: -0.33 Q3 '20: -0.28 Q4 '20: 0.17 Q1 '21: -0.29 Q2 '21: -0.35 Q3 '21: -0.13 Q4 '21: -0.91 Q1 '22: -0.83 Q2 '22: -0.94 Q3 '22: -1.36 Q4 '22: -1.40 Q1 '23: -1.39 Q2 '23: -1.35 Q3 '23: -1.27 Q4 '23: -1.21 Q1 '24: -1.14 Q2 '24: -1.50 Q3 '24: -1.46 Q4 '24: -1.59 Q1 '25: -2.74 Q2 '25: -2.24 Q3 '25: -2.15 Q4 '25: -1.84 Q1 '26: -0.43 Q2 '26: -0.43 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.